Myriam Curet McAdams - 21 Apr 2023 Form 4 Insider Report for INTUITIVE SURGICAL INC (ISRG)

Role: EVP & Chief Medical Officer
Signature: By: Donna Spinola For: Curet, Myriam
Issuer symbol: ISRG
Transactions as of: 21 Apr 2023
Net transactions value: -$1,505,793
Form type: 4
Filing time: 24 Apr 2023, 17:08:41 UTC
Previous filing: 01 Mar 2023
Next filing: 03 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ISRG	Common Stock	Options Exercise	$333,247	+2,000	+103%	$166.62	3,950	21 Apr 2023	Direct	F1
transaction	ISRG	Common Stock	Sale	$600,002	-2,000	-51%	$300.00	1,950	21 Apr 2023	Direct	F1
transaction	ISRG	Common Stock	Options Exercise	$1,045,540	+6,000	+308%	$174.26	7,950	21 Apr 2023	Direct	F1
transaction	ISRG	Common Stock	Sale	$1,800,007	-6,000	-75%	$300.00	1,950	21 Apr 2023	Direct	F1
transaction	ISRG	Common Stock	Sale	$333,071	-1,118	-57%	$297.92	832	21 Apr 2023	Direct	F1, F2
transaction	ISRG	Common Stock	Sale	$151,500	-505	-61%	$300.00	327	21 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ISRG	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-2,000	-31%	$0.000000	4,500	21 Apr 2023	Common Stock	2,000	$166.62	Direct	F1, F3
transaction	ISRG	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-6,000	-100%	$0.000000^*	0	21 Apr 2023	Common Stock	6,000	$174.26	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 10, 2023.
F2	The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.54 to $299.27 as follows: 232 shares sold at $296.54 - $297.32; 666 shares sold at $297.57 - $298.50; 220 shares sold at $298.62 - $299.27. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3	Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.